Resonant Capital Advisors LLC Acquires 5,950 Shares of Pfizer Inc. $PFE

Resonant Capital Advisors LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 117,214 shares of the biopharmaceutical company’s stock after acquiring an additional 5,950 shares during the period. Resonant Capital Advisors LLC’s holdings in Pfizer were worth $2,841,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Hixon Zuercher LLC increased its stake in Pfizer by 3.5% during the 2nd quarter. Hixon Zuercher LLC now owns 83,649 shares of the biopharmaceutical company’s stock worth $2,028,000 after purchasing an additional 2,866 shares in the last quarter. Ingalls & Snyder LLC boosted its holdings in shares of Pfizer by 7.4% in the second quarter. Ingalls & Snyder LLC now owns 755,313 shares of the biopharmaceutical company’s stock valued at $18,309,000 after buying an additional 51,993 shares during the period. Burke & Herbert Bank & Trust Co. increased its position in shares of Pfizer by 3.6% during the second quarter. Burke & Herbert Bank & Trust Co. now owns 79,749 shares of the biopharmaceutical company’s stock worth $1,933,000 after acquiring an additional 2,737 shares in the last quarter. CVA Family Office LLC raised its holdings in shares of Pfizer by 141.6% during the second quarter. CVA Family Office LLC now owns 12,502 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 7,327 shares during the period. Finally, AG2R LA Mondiale Gestion D Actifs lifted its position in Pfizer by 1.9% in the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 214,608 shares of the biopharmaceutical company’s stock valued at $5,202,000 after acquiring an additional 4,078 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PFE shares. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday. Finally, Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Stock Up 0.5%

PFE stock opened at $24.79 on Friday. The company has a market cap of $140.92 billion, a price-to-earnings ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17. The business has a 50 day moving average price of $24.87 and a two-hundred day moving average price of $24.18. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.